AML Clinical Trials

193 recruitingLast updated: June 17, 2026

There are 193 actively recruiting aml clinical trials across 36 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, New York, New York, United States, Tianjin, Tianjin Municipality, China. Updated daily from ClinicalTrials.gov.


AML Trials at a Glance

193 actively recruiting trials for aml are listed on ClinicalTrialsFinder across 6 cities in 36 countries. The largest study group is Phase 2 with 75 trials, with the heaviest enrollment activity in Houston, New York, and Tianjin. Lead sponsors running aml studies include Institute of Hematology & Blood Diseases Hospital, China, M.D. Anderson Cancer Center, and The First Affiliated Hospital of Soochow University.

Treatments under study

About AML Clinical Trials

Looking for clinical trials for AML? There are currently 43 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new AML trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about AML clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 193 trials

Recruiting
Phase 2

Ivosidenib as Post-HSCT Maintenance for AML

Acute Myeloid Leukemia (AML)IDH1 MutationHematopoietic Stem Cell Transplant (HSCT)
Massachusetts General Hospital75 enrolled5 locationsNCT06707493
Recruiting

Individualized AML Treatment

Relapsed/Refractory Acute Myeloid Leukemia (AML)
City of Hope Medical Center18 enrolled1 locationNCT07613385
Recruiting
Phase 2

Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia

Elderly PatientsNewly Diagnosed Acute Myeloid Leukemia (AML)
Chinese PLA General Hospital120 enrolled1 locationNCT07514936
Recruiting

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

Acute Myeloid Leukaemia (AML)Follicular Lymphoma ( FL)
Tempus AI550 enrolled6 locationsNCT07154823
Recruiting
Phase 1

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Gastric CancerAdvanced Solid TumorTNBC - Triple-Negative Breast Cancer+1 more
SillaJen, Inc.260 enrolled17 locationsNCT05768932
Recruiting
Phase 1

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Myelodysplastic SyndromesRelapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AML+1 more
Institut de Recherches Internationales Servier291 enrolled30 locationsNCT02074839
Recruiting
Not Applicable

Haplo-Cord HSCT for AML/MDS

MDS (Myelodysplastic Syndrome)AML (Acute Myeloid Leukemia)
Fujian Medical University Union Hospital82 enrolled4 locationsNCT07588360
Recruiting
Not Applicable

Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML

AML
Institute of Hematology & Blood Diseases Hospital, China27 enrolled1 locationNCT07490288
Recruiting
Phase 1Phase 2

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

Hodgkin LymphomaMultiple MyelomaAcute Myeloid Leukemia (AML)+7 more
M.D. Anderson Cancer Center80 enrolled1 locationNCT05092451
Recruiting

Symptom Cluster Heterogeneity and Gut Microbiota Mechanisms in Childhood Cancer Survivors

CancerGliomaLeukemia (Both ALL and AML)
The Children's Hospital of Zhejiang University School of Medicine600 enrolled1 locationNCT07450872
Recruiting
Phase 4

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

CholangiocarcinomaSolid Tumor MalignanciesGlioma+1 more
Rigel Pharmaceuticals16 enrolled2 locationsNCT07486713
Recruiting
Phase 3

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Acute Myeloid Leukemia (AML)
Kura Oncology, Inc.1,300 enrolled71 locationsNCT07007312
Recruiting

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Hodgkin LymphomaNon-Hodgkin LymphomaHematologic Malignancies+14 more
Center for International Blood and Marrow Transplant Research99,999 enrolled142 locationsNCT01351545
Recruiting

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Diffuse Large B Cell LymphomaHodgkin LymphomaNon-Hodgkin Lymphoma+16 more
Children's Hospital Medical Center, Cincinnati30 enrolled5 locationsNCT06131801
Recruiting
Phase 1

A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis

MyelofibrosisSecondary AML
Aspera Biomedicines, Inc.28 enrolled1 locationNCT07250646
Recruiting
Phase 1

First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)

Acute Myeloid LeukemiaR/R AMLR/R HR-MDS+1 more
Genmab78 enrolled9 locationsNCT07384715
Recruiting
Phase 1

A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS

Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia, in RelapseMyelodysplastic Syndrome With Excess Blasts+2 more
Apollo Therapeutics Ltd100 enrolled9 locationsNCT06372717
Recruiting
Phase 1Phase 2

Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML

AML
M.D. Anderson Cancer Center52 enrolled1 locationNCT07508982
Recruiting
Phase 2

A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)
Kyowa Kirin Co., Ltd.6 enrolled20 locationsNCT07623616
Recruiting
Phase 1

Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML

AMLRefractory/Relapse Acute Myeloid Leukemia
Peking University People's Hospital27 enrolled1 locationNCT07617285